Screening data from 19 patients with late‐onset Pompe disease for a phase I clinical trial of AAV8 vector‐mediated gene therapy

Late‐onset Pompe disease (LOPD) is a multisystem disorder with significant myopathy. The standard treatment is enzyme replacement therapy (ERT), a therapy that is lifesaving, yet with limitations. Clinical trials have emerged for other potential treatment options, including adeno‐associated virus (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Hannah, William B., Case, Laura E., Smith, Edward C., Walters, Crista, Bali, Deeksha, Kishnani, Priya S., Koeberl, Dwight D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2023
Materias:
Research Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494494/
https://www.ncbi.nlm.nih.gov/pubmed/37701327
http://dx.doi.org/10.1002/jmd2.12391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494494/
https://www.ncbi.nlm.nih.gov/pubmed/37701327
http://dx.doi.org/10.1002/jmd2.12391

Ejemplares similares